Related Experiment Videos
[Lymphomas of the skin]
T Nagatani1, N Baba, H Nakajima
1Dept. of Dermatology, Yokohama City University School of Medicine.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|August 1, 1993
Summary
Cutaneous lymphomas, including T-cell and B-cell types, require tailored treatments based on stage and risk. Advanced stages necessitate combination chemotherapy, while milder options like deoxycoformycin plus interferon are suitable for older patients.
Area of Science:
- Dermatology
- Oncology
- Hematology
Context:
- Malignant lymphoma of the skin is an extranodal lymphoma primarily affecting the skin.
- In Japan, 80-90% of cutaneous lymphomas exhibit a T-cell phenotype, commonly Mycosis Fungoides (MF) and Sézary Syndrome (SS).
- Cutaneous B-cell lymphomas (CBCL) are often associated with poor prognosis, though some early-stage cases have a benign outlook.
Purpose:
- To review treatment strategies for various stages of cutaneous T-cell lymphoma (CTCL) and cutaneous B-cell lymphoma (CBCL).
- To highlight therapeutic options for low, intermediate, and high-risk groups of these lymphomas.
- To emphasize the need for effective chemotherapy in advanced stages and milder options for elderly patients.
Summary:
- Low-risk CTCL (Stages IA-IIA) is treated with topical therapies like steroids, PUVA, and interferons.
- Intermediate-risk CTCL (Stages IIB-III) and early CBCL (Stages I-II) may receive electron-beam irradiation, retinoids, interferons, photopheresis, or deoxycoformycin (DCF) plus interferon.
- Advanced-stage CTCL and CBCL (Stage IV for CTCL, Stages III-IV for CBCL) require multiagent chemotherapy (e.g., MACOP-B, M-BACOD, ProMACE-CytaBOM), with DCF plus interferon recommended for older patients.
Impact:
- Provides a comprehensive overview of current treatment guidelines for cutaneous lymphomas.
- Differentiates therapeutic approaches based on lymphoma subtype, stage, and patient risk factors.
- Informs clinical decision-making for managing these complex skin cancers.